GENFLOW BIOSCIENCES PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.1 GBX | 0.00% |
|
-1.59% | +117.54% |
| May. 30 | Genflow Biosciences receives 50% of grant for sarcopenia project | AN |
| May. 30 | Genflow Biosciences Secures Grant for Sarcopenia Research Program | MT |
Financials (USD)
| Sales 2022 | - | Sales 2023 | - | Capitalization | 4.17M |
|---|---|---|---|---|---|
| Net income 2022 | -1M | Net income 2023 | -1M | EV / Sales 2022 | - |
| Net cash position 2022 | 2.36M | Net cash position 2023 | 684K | EV / Sales 2023 | - |
| P/E ratio 2022 |
-5.26
x | P/E ratio 2023 |
-2.56
x | Employees | 5 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 36.13% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | -1.59% | ||
| Current month | +1.64% | ||
| 1 month | +67.57% | ||
| 3 months | +106.67% | ||
| 6 months | +96.83% | ||
| Current year | +117.54% |
1 week
3.00
3.30
1 month
1.803.41
Current year
1.323.41
1 year
1.323.90
3 years
1.3213.50
5 years
1.3213.50
10 years
1.3213.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 66 | 19-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 64 | 22-06-28 | |
Tamara Joseph
CHM | Chairman | 61 | 22-06-28 |
| Founder | 66 | 19-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-10 | 3.1 | 0.00% | 3,930,884 |
| 24-06-07 | 3.1 | 0.00% | 865,856 |
| 24-06-06 | 3.1 | -3.13% | 1,203,746 |
| 24-06-05 | 3.2 | -3.03% | 1,481,612 |
| 24-06-04 | 3.3 | +4.76% | 421,826 |
Delayed Quote London S.E., June 10, 2024 at 11:35 am EDT
More quotes
Genflow Biosciences Plc is a United Kingdom-based biotechnology company. The Company is engaged in developing gene therapies designed to target the aging process and to reduce and delay the incidence of age-related diseases, which is done through therapeutics targeting aging in humans by using adeno-associated virus (AAV) vectors to deliver copies of the Sirtuin-6 (SIRT6) gene variant that is found in centenarians into cells. The Company's product line includes GF-1002, GF-3001 and GF-4001. GF-4001. GF-1002 is a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. GF-4001 is a non-human version of GF-1002 anti-ageing gene therapy developed for veterinary use (dogs). GF-3001 is a formulation of an adeno-associated viral vector-based gene therapy. The Company has operations in the United Kingdom and Belgium.
Calendar
2024-06-27
- Annual Genearl Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| +117.54% | 13.79M | |
| +18.77% | 125B | |
| +14.05% | 108B | |
| -7.16% | 24.21B | |
| +2.07% | 22.78B | |
| -10.79% | 17.96B | |
| -41.74% | 16.43B | |
| -13.47% | 16.37B | |
| +2.23% | 13.58B | |
| +27.13% | 11.66B |
- Stock Market
- Equities
- GENF Stock
